WO2014119479A1 - デスモシン、イソデスモシン、およびその誘導体の製造方法 - Google Patents
デスモシン、イソデスモシン、およびその誘導体の製造方法 Download PDFInfo
- Publication number
- WO2014119479A1 WO2014119479A1 PCT/JP2014/051482 JP2014051482W WO2014119479A1 WO 2014119479 A1 WO2014119479 A1 WO 2014119479A1 JP 2014051482 W JP2014051482 W JP 2014051482W WO 2014119479 A1 WO2014119479 A1 WO 2014119479A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- general formula
- compound
- group
- compound represented
- salt
- Prior art date
Links
- 0 *C(*)CCCCN Chemical compound *C(*)CCCCN 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
Definitions
- the present invention relates to a method for producing desmosine, isodesmosine, and derivatives thereof and analogs thereof.
- COPD chronic obstructive pulmonary disease
- WHO World Health Organization
- COPD chronic obstructive pulmonary disease
- COPD the pathological condition is extremely complicated and there are many unknown parts, and there is no fundamental therapeutic drug.
- the rapid increase in the number of COPD patients around the world is feared due to the increase in smokers in developing countries and air pollution due to industrial development, so the establishment of a rapid and simple test method has become a top priority.
- Non-patent documents 1 and 2 describe techniques relating to the total synthesis of desmosine.
- Non-Patent Document 3 As a technique relating to the synthesis method of a compound having a pyridine ring.
- the present invention provides a novel production method for stably obtaining desmosine, isodesmosine or a derivative thereof with few steps.
- a method for producing a compound represented by the following general formula (I) or a salt thereof, (In the general formula (I), one of R 1 and R 2 is a —CH 2 CH 2 CH 2 CH (NH 2 ) COOH group, and the other is a hydrogen atom.
- One or more hydrogen atoms, one or more carbon atoms, or one or more nitrogen atoms may be substituted with an isotope.
- a compound represented by the following general formula (XII) or a salt thereof and a compound represented by the following general formula (XIII) are reacted in the presence of a compound represented by the following general formula (XIV) to give the following general formula (XV)
- the manufacturing method including the process of forming the compound shown by its salt is provided.
- X 1 is an amino group that may be protected
- Y 1 is a carboxyl group that may be protected.
- one or two The above hydrogen atom, one or more carbon atoms, or one or more nitrogen atoms may be substituted with an isotope.
- M (OTf) 3 (XIV)
- M is a trivalent metal atom
- Tf is a trifluoromethylsulfonyl group.
- X 1 and Y 1 are the same as X 1 and Y 1 in the general formula (XII), respectively
- X 2 and Y 2 are X 2 and X in the general formula (XIII), respectively.
- R 17 and R 18 are -CH 2 CH 2 CH 2 CHX 2 Y 2 group, the other is a hydrogen atom, X 2 and Y 2 are each the formula X 2 and Y 2 in (XIII), and in the general formula (XV), one or more hydrogen atoms, one or more carbon atoms, or one or two or more nitrogen atoms are (It may be substituted with an isotope.)
- a method for producing a compound represented by the following general formula (I) or a salt thereof, (In the general formula (I), one of R 1 and R 2 is a —CH 2 CH 2 CH 2 CH (NH 2 ) COOH group, and the other is a hydrogen atom.
- One or more hydrogen atoms, one or more carbon atoms, or one or more nitrogen atoms may be substituted with an isotope.
- a compound represented by the following general formula (II) or a salt thereof and a compound represented by the following general formula (III) are reacted in the presence of a lanthanoid compound represented by the following general formula (IV) to give the following general formula (V ) Or a salt thereof, forming a compound, Converting the compound represented by the general formula (V) or a salt thereof into the compound represented by the general formula (I) or a salt thereof; A manufacturing method is provided.
- R 3 represents a tert-butyloxycarbonyl group or a benzyloxycarbonyl group
- R 4 represents a tert-butyl group, a benzyl group, a methyl group, or an ethyl group.
- each R 5 independently represents a tert-butyloxycarbonyl group or a benzyloxycarbonyl group
- R 6 represents a tert-butyl group, a benzyl group, a methyl group or an ethyl group.
- Ln (OTf) 3 (IV)
- Ln is La, Pr, Nd, Gd, Sc, Y, Dy, Er, or Yb
- Tf is a trifluoromethylsulfonyl group.
- R 3 and R 4 are identical to R 3 and R 4 in the general formula respectively (II)
- R 5 and in the formula R 5 and R 6 are each (III) R 6 and the same.
- R 7 and R 8 are -CH 2 CH 2 CH 2 CH ( N (R 5) 2) a COOR 6 group, the other is a hydrogen atom, R 5 and R 6 is the same as R 5 and R 6 in the general formula (III), and in the general formula (V), one or two or more hydrogen atoms, one or two or more carbon atoms, Two or more nitrogen atoms may be substituted with isotopes.
- desmosine, isodesmosine or a derivative thereof or an analog thereof can be stably obtained with few steps.
- the present embodiment relates to a production method represented by the following general formula (I).
- the manufacturing method in the present embodiment includes the following steps.
- Step 21 A compound represented by the following general formula (XII) or a salt thereof and a compound represented by the following general formula (XIII) are reacted in the presence of a compound represented by the following general formula (XIV), Forming a compound represented by the formula (XV) or a salt thereof:
- X 1 is an amino group that may be protected, and Y 1 is a carboxyl group that may be protected.
- XII one or two The above hydrogen atom, one or more carbon atoms, or one or more nitrogen atoms may be substituted with an isotope.
- X 2 is an amino group which may be protected, and Y 2 is a carboxyl group which may be protected. Also, in the general formula (XIII), one or two The above hydrogen atom, one or more carbon atoms, or one or more nitrogen atoms may be substituted with an isotope.
- M (OTf) 3 (XIV) In the general formula (XIV), M is a trivalent metal atom, and Tf is a trifluoromethylsulfonyl group.
- X 1 and Y 1 are the same as X 1 and Y 1 in the general formula (XII), respectively, and X 2 and Y 2 are X 2 and X in the general formula (XIII), respectively.
- Y 2 and are identical.
- one of R 17 and R 18 are -CH 2 CH 2 CH 2 CHX 2 Y 2 group, the other is a hydrogen atom, X 2 and Y 2 are each the formula X 2 and Y 2 in (XIII), and in the general formula (XV), one or more hydrogen atoms, one or more carbon atoms, or one or two or more nitrogen atoms are (It may be substituted with an isotope.)
- one of R 1 and R 2 is a —CH 2 CH 2 CH 2 CH (NH 2 ) COOH group, and the other is a hydrogen atom.
- One or more hydrogen atoms, one or more carbon atoms, or one or more nitrogen atoms may be substituted with an isotope.
- step 21 lysine, which is a compound having an amino group, or a protected form thereof, or a salt thereof, and allicin, which is a compound having an aldehyde group, or a protected form thereof, are used as raw materials, and metal trifluoromethanesulfonate is used as a catalyst.
- a pyridine ring is formed to obtain a compound represented by the general formula (XV) or a salt thereof.
- the compound represented by the general formula (XII) or a salt thereof is used as the compound having an amino group.
- X 1 is an amino group that may be protected
- Y 1 is a carboxyl group that may be protected.
- Specific examples of the protecting group when X 1 is a protected amino group and specific examples of the protecting group when Y 1 is a protected carboxyl group will be described in the second embodiment.
- Specific examples of the salt of the compound represented by the general formula (XII) include a hydrochloride of a terminal amine in the general formula (XII), a trifluoromethanesulfonate, and the like. By using these salts, for example, water solubility can be increased.
- the compound shown in general formula (XIII) is used as a compound which has an aldehyde group.
- X 2 is an amino group that may be protected
- Y 2 is a carboxyl group that may be protected.
- Specific examples of the protecting group when X 2 is a protected amino group and specific examples of the protecting group when Y 2 is a protected carboxyl group will be described in the second embodiment. .
- the amount of the compound represented by the general formula (XIII) used in the step 21 is not particularly limited as long as it does not interfere with the target reaction.
- the amount used is 1 for the compound represented by the general formula (XII).
- the molar equivalent or more preferably 3 molar equivalents or more, for example, 20 molar equivalents or less, preferably 10 molar equivalents or less.
- the compound represented by the general formula (XIII) can be synthesized using a known method. Specific examples of the synthesis method will be described later in the Examples section.
- the compound represented by the general formula (XIV) is a metal trifluoromethanesulfonate and functions as a catalyst for Chichibabin pyridine synthesis reaction.
- the compound represented by the general formula (XIV) functions as a Lewis acid that is stable in, for example, a protic solvent.
- M represents a trivalent metal atom.
- M include lanthanoid metals and transition metals.
- Specific examples of the lanthanoid metal include La, Pr, Nd, Gd, Sc, Y, Dy, Er, Yb, Sm, Eu, Tb, Ho, Tm, and Lu, and more specifically in the second implementation. Those described in the embodiments can be used.
- Specific examples of the transition metal include Cu, Fe, and Zn.
- the solvent used in the reaction is not particularly limited as long as it is stable under the reaction conditions and does not interfere with the target reaction.
- water alcohols such as ethanol and methanol; and acetone, dimethylformamide, dimethylsulfate
- polar aprotic solvents such as foxides; and other organic solvents
- the reaction solvent is, for example, water.
- a mixed solvent of water and alcohol can be used, and more specifically, a mixed solvent of water and methanol can be used.
- the amount of the solvent used can be, for example, about 0.001 to 1 times the amount of the compound represented by the general formula (XII), and preferably 0.01 to 0.02 times the amount of the substance.
- the reaction temperature can be, for example, from about ⁇ 20 ° C. to the boiling point of the solvent, but is preferably 20 ° C. or higher from the viewpoint of the reaction rate. Moreover, 100 degrees C or less is preferable from a stability viewpoint of a product.
- the reaction time can be set according to the reaction temperature, stirring efficiency, etc., and is, for example, about 12 to 24 hours.
- Step 21 when the reaction solvent is water, selective synthesis of desmosine or a derivative thereof and isodesmosine or a derivative thereof becomes possible.
- isodesmosine or a derivative thereof can be selectively obtained by setting the reaction solvent to water and the reaction temperature to 70 ° C. or higher, preferably 75 ° C. or higher, and 100 ° C. or lower.
- both desmosine or a derivative thereof and isodesmosine or a derivative thereof by setting the reaction solvent to water and the reaction temperature to be 0 ° C or higher, preferably 15 ° C or higher, and 60 ° C or lower, preferably 40 ° C or lower. Can be obtained in the same step.
- the amount of the solvent used can be, for example, about 0.001 to 1 times the amount of the compound represented by the general formula (XII), and 0.01 to 0.02 substance.
- the amount is preferably doubled.
- the reaction temperature can be, for example, from about ⁇ 20 ° C. to the boiling point of the solvent, but is preferably 20 ° C. or higher from the viewpoint of the reaction rate. Moreover, 100 degrees C or less is preferable from a stability viewpoint of a product. Moreover, it is also preferable to set it as 0 degrees C or less.
- the reaction time can be set according to the reaction temperature, stirring efficiency, etc., and is, for example, about 12 to 24 hours.
- the step further includes the following steps after the step 21: May be: (Step 22) A step of converting the compound represented by the general formula (XV) or a salt thereof into the compound represented by the general formula (I) or a salt thereof.
- step 22 the amino group and the carboxyl group in the compound of general formula (XV) obtained in step 21 are deprotected to obtain the compound represented by general formula (I).
- the deprotection method in step 22 will be described more specifically in the second embodiment.
- X 1 and Y 1 in the general formula (XII) and X 2 and Y 2 in the general formula (XIII) are protected amino groups or carboxyl groups
- the general formula ( X 1 in XII) and X 2 in general formula (XIII) are preferably the same group
- Y 1 in general formula (XII) and Y 2 in general formula (XIII) are preferably the same group.
- X 1 , Y 1 , X 2 and Y 2 are groups that can be removed in the same step.
- the amino acid represented by the general formula (XII) or a derivative thereof and the amino acid aldehyde represented by (XIII) are used as raw materials, and the metal trifluoromethanesulfonate represented by the general formula (XIV) is catalyzed.
- the metal trifluoromethanesulfonate represented by the general formula (XIV) is catalyzed.
- the present embodiment relates to a production method represented by the following general formula (I).
- the manufacturing method in the present embodiment includes the following steps.
- Step 11 A compound represented by the following general formula (II) or a salt thereof and a compound represented by the following general formula (III) are reacted in the presence of a lanthanoid compound represented by the following general formula (IV).
- step 12 A step of forming a compound represented by the general formula (V) or a salt thereof; and (step 12) a step of converting the compound represented by the general formula (V) or a salt thereof into the compound represented by the general formula (I) or a salt thereof. .
- R 3 is tert- butyloxycarbonyl group (hereinafter, also referred to as "Boc group”.) Or benzyloxycarbonyl group (hereinafter, is also referred to as "Cbz group”.), R 4 during the tert- butyl group (hereinafter, also referred to as "t Bu group”.), benzyl group (hereinafter, also referred to as "Bn group”.), a methyl group or an ethyl group.
- the above formula (II) One or more hydrogen atoms, one or more carbon atoms, or one or more nitrogen atoms may be substituted with an isotope.
- each R 5 independently represents a Boc group or a Cbz group
- R 6 represents a t Bu group, a Bn group, a methyl group, or an ethyl group.
- the general formula (III) Among them, one or more hydrogen atoms, one or more carbon atoms, or one or more nitrogen atoms may be substituted with an isotope.
- Ln (OTf) 3 (IV) (In the general formula (IV), Ln is La, Pr, Nd, Gd, Sc, Y, Dy, Er, or Yb, and Tf is a trifluoromethylsulfonyl group.)
- R 3 and R 4 are identical to R 3 and R 4 in the general formula respectively (II), R 5 and in the formula R 5 and R 6 are each (III) R 6 and the same. also, one of R 7 and R 8 are -CH 2 CH 2 CH 2 CH ( N (R 5) 2) a COOR 6 group, the other is a hydrogen atom, R 5 and R 6 is the same as R 5 and R 6 in the general formula (III), and in the general formula (V), one or two or more hydrogen atoms, one or two or more carbon atoms, Two or more nitrogen atoms may be substituted with isotopes.
- R 1 and R 2 are a —CH 2 CH 2 CH 2 CH (NH 2 ) COOH group, and the other is a hydrogen atom.
- R 1 is a —CH 2 CH 2 CH 2 CH (NH 2 ) COOH group
- the compound in which R 2 is a hydrogen atom is desmosine shown in formula (1).
- a compound in which R 1 is a hydrogen atom and R 2 is —CH 2 CH 2 CH 2 CH (NH 2 ) COOH group is isodesmosine represented by the formula (2).
- it demonstrates still more concretely in order of the process 11 and the process 12.
- a pyridine ring is formed by Chichibabin pyridine synthesis using a lysine protected body, which is a compound having an amino group, or a salt thereof and an allicin protected body, which is a compound having an aldehyde group, as raw materials, and a lanthanoid compound as a catalyst.
- a compound represented by the general formula (V) or a salt thereof is obtained.
- the compound represented by the general formula (II) or a salt thereof is used as the compound having an amino group.
- R 3 is a Boc group or a Cbz group, preferably a Boc group.
- R 4 represents a t Bu group, a Bn group, a methyl group or an ethyl group, and preferably a t Bu group.
- Specific examples of the salt of the compound represented by the general formula (II) include a hydrochloride of a terminal amine in the general formula (II), a trifluoromethanesulfonate, and the like. By using these salts, for example, water solubility can be increased.
- R 5 is a Boc group or a Cbz group, preferably a Boc group.
- the two R 5 groups may be the same or different, but are preferably the same group, and more preferably the two R 5 groups are both Boc groups.
- R 6 is t Bu group, Bn group, a methyl group or an ethyl group, preferably Bn group or t Bu group.
- R 3 in general formula (II) and R 5 in general formula (III) are the same group, and R 4 in general formula (II) and general R 6 in formula (III) is preferably the same group. Further, it is preferable that R 3 to R 6 are groups that can be removed in the same step. Specifically, R 3 in general formula (II) and R 5 in general formula (III) are both Boc groups, R 4 in general formula (II) and R 6 in general formula (III) Are preferably t Bu groups. Thereby, in step 12, R 3 to R 6 can be deprotected in one step.
- the amount of the compound represented by the general formula (III) is not particularly limited as long as it does not interfere with the target reaction. For example, 3 mole equivalents or more with respect to the compound represented by the general formula (II) It can be 20 molar equivalents or less.
- the compound shown in general formula (III) is compoundable using a well-known method. Specific examples of the synthesis method will be described later in the Examples section.
- Ln represents a lanthanoid metal, specifically, La, Pr, Nd, Gd, Sc, Y, Dy, Er, or Yb.
- Preferred examples of Ln include Pr and La, and Pr is more preferred.
- other metal salts described in the first embodiment can be used instead of the Ln salt represented by the general formula (IV).
- the solvent used in the reaction is not particularly limited as long as it is stable under the reaction conditions and does not interfere with the target reaction.
- water alcohols such as ethanol and methanol; and acetone, dimethylformamide, dimethylsulfate
- polar aprotic solvents such as foxides; and other organic solvents
- a mixed solvent of water and alcohol is preferably used, and a mixed solvent of water and methanol is more preferable.
- the amount of the solvent used can be, for example, about 0.001 to 1 times the amount of the compound represented by the general formula (II), and is preferably 0.01 to 0.02 times the amount of the substance.
- the reaction temperature can be, for example, from about ⁇ 20 ° C. to the boiling point of the solvent, but is preferably 20 ° C. or higher from the viewpoint of the reaction rate. Moreover, 100 degrees C or less is preferable from a stability viewpoint of a product. Moreover, it is also preferable to set it as 0 degrees C or less from a viewpoint of stability of a product.
- the reaction time can be set according to the reaction temperature, stirring efficiency, etc., and is, for example, about 12 to 24 hours.
- step 11 the structure of the compound represented by the general formula (V), which is a product, can be controlled by controlling the type of solvent or the pH of the solvent and the raw material charge ratio. Specifically, it is possible to control which of R 7 and R 8 is a —CH 2 CH 2 CH 2 CH (N (R 5 ) 2 ) COOR 6 group, and a desmosine derivative and an isodesmosine derivative And making it possible. For example, when a mixed solvent of water and methanol is used, the ratio of ethanol to water is greater than 0 volume times and 10 volume times or less, and the compound represented by general formula (III) is compared with the compound represented by general formula (II).
- R 8 is a —CH 2 CH 2 CH 2 CH (N (R 5 ) 2 ) COOR 6 group and R 7 is a hydrogen atom
- R 8 is a —CH 2 CH 2 CH 2 CH (N (R 5 ) 2 ) COOR 6 group and R 7 is a hydrogen atom
- R 8 is a —CH 2 CH 2 CH 2 CH (N (R 5 ) 2 ) COOR 6 group and R 7 is a hydrogen atom
- R 7 is a hydrogen atom
- step 12 the amino group and the carboxyl group in the compound of general formula (V) obtained in step 11 are deprotected to obtain the compound represented by general formula (I).
- R 3 in the general formula (II) and R 5 in the general formula (III) are both Boc groups
- R 4 in the general formula (II) is a t Bu group
- the general formula (III) When R 6 therein is a Bn group, the Bn group is removed by catalytic reduction using, for example, hydrogen and palladium on carbon (Pd / C).
- the conditions for catalytic reduction are, for example, Pd / C 500 mol /%, room temperature (25 ° C., the same applies hereinafter), and 24 hours.
- TFA trifluoroacetic acid
- R 3 in general formula (II) and R 5 in general formula (III) are both Boc groups
- R 4 in general formula (II) and R 6 in general formula (III) are both the case is t Bu group, for example, by acid treatment with trifluoroacetic acid (TFA) aqueous solution or the like, it is possible to remove the Boc group and t Bu groups in the same step.
- TFA trifluoroacetic acid
- Step 10 A step of converting a compound represented by the general formula (VI) or a salt thereof into a compound represented by the general formula (II) or a salt thereof.
- R 3 is the same as R 3 in the general formula (II), and R 9 is a Boc group or a Cbz group and is a group different from R 3.
- Step 10 includes the following steps, for example.
- Step 10-1 a step of converting a compound represented by the general formula (VI) into a compound represented by the following general formula (VII), and
- Step 10-2 a compound represented by the general formula (VII) represented by the general formula ( A step of converting to the compound shown in II) or a salt thereof.
- Step 10-1 is a step of protecting the carboxyl group of the compound represented by the formula (VI).
- a known method can be used depending on the kind of the protecting group R 4 .
- a commercially available compound can be used as the compound represented by the formula (VI).
- R 4 is a t Bu groups, such as the method described below in the example section, it is preferable to t Bu by reaction using ureas.
- Step 10-2 is a step of removing the amino protecting group R 9 of the compound represented by the formula (VII). Also in this step, a known method can be used depending on the kind of the protecting group R 9 . For example, when R 9 is a Cbz group, the Cbz group is removed by catalytic reduction using hydrogen and palladium carbon (Pd / C). The conditions for the catalytic reduction are, for example, Pd / C 5 mol /%, room temperature and 2 hours. Further, when R 9 is a Boc group, a removal method using TFA is preferable. The compound obtained in Step 10 can be used as a raw material in Step 11.
- the same effect as the first embodiment can be obtained.
- Chichibabin pyridine synthesis using a lanthanoid compound as a catalyst is a key reaction.
- Desmosine, isodesmosine, and derivatives thereof can be obtained in a high yield with a small number of steps. Further, it is possible to stably form a pyridine ring and to control the position of the side chain of the pyridine ring.
- one or more hydrogen atoms, one or more carbon atoms, or one or more nitrogen atoms are substituted with isotopes. May be.
- one or more hydrogen atoms may be substituted with deuterium (D).
- One or two or more carbon atoms ( 12 C) may be substituted with 13 C.
- One or two or more nitrogen atoms ( 14 N) may be substituted with 15 N.
- a compound that can be used as a COPD biomarker can be stably obtained by isotopically labeling the compound represented by the general formula (I) with deuterium or the like.
- the element to be labeled with an isotope may be one type or two or more types. Further, there is no particular limitation on the number of isotope-labeled atoms in the compound. For example, when the compound represented by the general formula (I) or a salt thereof is used as a biomarker in mass spectrometry, the molecular weight of the isotope-labeled compound is, for example, 3 or more than the molecular weight of the compound before isotope-labeling Increase, preferably increase 4 or more.
- the pyridine ring is constituted rather than isotopically labeling the side chain at the 1-position (N-position) of the pyridine ring. It is preferred that the side chain attached to the carbon atom is isotopically labeled. Further, nitrogen or carbon atoms constituting the pyridine ring may be isotopically substituted.
- the position to be deuterated is not particularly limited, but it is preferable to deuterate the hydrogen atom in the side chain bonded to the pyridine ring. More preferably, the hydrogen atom in the side chain bonded to the carbon atom constituting the pyridine ring is deuterated, and the side chain bonded to the carbon atom constituting the pyridine ring is bonded to the carbon atom constituting the main chain. More preferably, the hydrogen atom to be deuterated is deuterated.
- Scheme 1 illustrates an example of introducing 13 C and D into a compound represented by formula (I).
- 13 C and D are each introduced one by one into the allicin protector, that is, the compound represented by the general formula (III). Specific examples of the method for synthesizing the compound represented by the general formula (III) will be described later in the Examples section.
- 13 C may be formed during the Wittig reaction.
- D is introduced at the ⁇ -position by hydroboration oxidation.
- Step 11 by using the above isotope-labeled compound as the compound represented by the general formula (III), the carbon atom constituting the pyridine ring is isotopically substituted, and the carbon atom constituting the pyridine ring is substituted.
- the hydrogen atom in the side chain attached to can be deuterated.
- Scheme 2 illustrates an example of introducing 13 C and 15 N into the compound represented by formula (I).
- one 13 C is introduced into the allicin-protected product, ie, the compound represented by the general formula (III), and 15 N is introduced into the lysine-protected product, ie, the compound represented by the general formula (II).
- 13 C is introduced into the allicin-protected form in the Wittig reaction, and a commercially available lysine-protected form containing 15 N is used to synthesize the compound represented by the formula (I). Since D is not used, it is preferable in that it is difficult to reduce the isotope ratio.
- Step 11 by using the above isotope-labeled compounds as the compounds represented by the general formula (II) and the general formula (III), the carbon atom and the nitrogen atom constituting the pyridine ring are isotopically substituted. can do.
- Scheme 3 illustrates an example in which four D are introduced into the compound represented by formula (I).
- two Ds are introduced into the allicin protector, that is, the compound represented by the general formula (III).
- an introduction method for example, a method of performing hydroboration oxidation twice from aspartic acid or glutamic acid can be mentioned.
- Step 11 by using the above deuterated compound as the compound represented by the general formula (III), the hydrogen atom in the side chain bonded to the carbon atom constituting the pyridine ring is deuterated. Can do.
- One or more hydrogen atoms, one or more carbon atoms, or one or more nitrogen atoms may be substituted with an isotope.
- a compound represented by the following general formula (II) or a salt thereof and a compound represented by the following general formula (III) are reacted in the presence of a lanthanoid compound represented by the following general formula (IV) to give the following general formula (V ) Or a salt thereof, forming a compound, Converting the compound represented by the general formula (V) or a salt thereof into the compound represented by the general formula (I) or a salt thereof; Manufacturing method.
- R 3 represents a tert-butyloxycarbonyl group or a benzyloxycarbonyl group
- R 4 represents a tert-butyl group, a benzyl group, a methyl group, or an ethyl group.
- each R 5 independently represents a tert-butyloxycarbonyl group or a benzyloxycarbonyl group
- R 6 represents a tert-butyl group, a benzyl group, a methyl group or an ethyl group.
- Ln (OTf) 3 (IV)
- Ln is La, Pr, Nd, Gd, Sc, Y, Dy, Er, or Yb
- Tf is a trifluoromethylsulfonyl group.
- R 3 and R 4 are identical to R 3 and R 4 in the general formula respectively (II)
- R 5 and in the formula R 5 and R 6 are each (III) R 6 and the same.
- R 7 and R 8 are -CH 2 CH 2 CH 2 CH ( N (R 5) 2) a COOR 6 group, the other is a hydrogen atom, R 5 and R 6 is the same as R 5 and R 6 in the general formula (III), and in the general formula (V), one or two or more hydrogen atoms, one or two or more carbon atoms, Two or more nitrogen atoms may be substituted with isotopes.
- the manufacturing method which further includes the process of converting the compound or its salt shown by the following general formula (VI) into the compound or its salt shown by the said general formula (II).
- R 3 is the same as R 3 in the general formula (II), R 9 is a tert-butyloxycarbonyl group or a benzyloxycarbonyl group and is a group different from R 3. is there.
- [3] The production method according to [1] or [2], wherein the step of forming the compound represented by the general formula (V) is performed in a mixed solvent of alcohol and water.
- Compound 6 (2- (S) -Bis-tert-butoxycarbonylamino-6-oxo-hexanoic acid benzyl ester)
- Example 1 total synthesis of isodesmosine was performed using the compound 6 obtained in Synthesis Example 1.
- Example 2 In Example 1, the solvent composition for obtaining Compound 28 from Compound 5 and Compound 6 was changed, and the synthesis reaction was performed according to Example 1. That is, with respect to the reaction solvent, the water / methanol was changed to 2/1 in Example 1, the water / methanol was changed to 3/1 in this example, and the compound 28 was synthesized according to Example 1 for other than that. did. As a result, also in this example, Compound 28 was obtained in a yield of 24%.
- Example 3 This example relates to the synthesis of Chichibabin pyridine, which was able to synthesize desmosine and isodesmosine all at once. Specifically, in this example, desmosine and isodesmosine were totally synthesized using Compound 54 obtained in Synthesis Example 2 and Compound 5 ′ obtained in Synthesis Example 3.
- Example 4 In Example 3, the charged composition ratio of Compound 5 ′ and Compound 54 in obtaining Compounds 55 and 56 from Compound 5 ′ and Compound 54 was changed, and other than that, the synthesis reaction was performed according to Example 3. Further, the compound 5 used in Example 1 was used in place of the compound 5 ′, and the charged composition ratio of the compound 5 and the compound 54 was changed, and the other components were subjected to the synthesis reaction according to Example 1. The results are shown in Table 1. From Table 1, the yield of the synthesis intermediate of desmosine or the synthesis intermediate of isodesmosine can be adjusted by adjusting the raw material charge ratio and the solvent composition ratio.
- Example 5 In Example 3, the type of Ln (OTf) 3 used as the catalyst was changed, and the others were subjected to the synthesis reaction according to Example 1. The results are shown in Table 2. From Table 2, when various Ln (OTf) 3 was used, a synthesis intermediate of desmosine and a synthesis intermediate of isodesmosine were obtained.
- Example 6 In Example 3, the charged composition ratio of Compound 5 ′ and Compound 54 and the reaction temperature when obtaining Compounds 55 and 56 from Compound 5 ′ and Compound 54 were changed, and the synthesis reaction was performed according to Example 1 for the others. I did it. The results are shown in Table 3. From Table 3, the synthesis intermediate of isodesmosine could be selectively obtained by setting the reaction temperature to 80 ° C. or 100 ° C. On the other hand, at room temperature or 40 ° C., a synthesis intermediate of desmosine and a synthesis intermediate of isodesmosine could be obtained.
- Example 7 a desmosine labeled product and an isodesmosine labeled product in which carbon atoms and nitrogen atoms constituting the pyridine ring are isotopically labeled were synthesized.
- [(6) - 13 C] -N shown in N-Bis [(1,1-dimethylethoxy ) carbonyl] -6-oxo-1,1-dimethylethyl Scheme 7
- the synthetic procedure of Ester (Compound 24).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
下記一般式(I)に示される化合物またはその塩の製造方法であって、
下記一般式(XII)に示される化合物またはその塩と下記一般式(XIII)に示される化合物とを下記一般式(XIV)に示される化合物の存在下に反応させて、下記一般式(XV)またはその塩に示される化合物を形成する工程を含む、製造方法が提供される。
M(OTf)3 (XIV)
(上記一般式(XIV)中、Mは3価の金属原子であり、Tfはトリフルオロメチルスルホニル基である。)
下記一般式(I)に示される化合物またはその塩の製造方法であって、
下記一般式(II)に示される化合物またはその塩と下記一般式(III)に示される化合物とを下記一般式(IV)に示されるランタノイド化合物の存在下に反応させて、下記一般式(V)またはその塩に示される化合物を形成する工程と、
前記一般式(V)に示す化合物またはその塩を前記一般式(I)に示した化合物またはその塩に変換する工程と、
を含む、製造方法が提供される。
Ln(OTf)3 (IV)
(上記一般式(IV)中、LnはLa、Pr、Nd、Gd、Sc、Y、Dy、ErまたはYbであり、Tfはトリフルオロメチルスルホニル基である。)
本実施形態は、下記一般式(I)に示される製造方法に関する。本実施形態における製造方法は、以下の工程を含む。
(工程21)下記一般式(XII)に示される化合物またはその塩と下記一般式(XIII)に示される化合物とを下記一般式(XIV)に示される化合物の存在下に反応させて、下記一般式(XV)またはその塩に示される化合物を形成する工程。
M(OTf)3 (XIV)
(上記一般式(XIV)中、Mは3価の金属原子であり、Tfはトリフルオロメチルスルホニル基である。)
また、一般式(XII)に示した化合物の塩の具体例として、一般式(XII)における末端アミンの塩酸塩、トリフルオロメタンスルホン酸塩等が挙げられる。これらの塩を用いることにより、たとえば水溶性を高めることができる。
なお、一般式(XIII)に示した化合物は、公知の方法を用いて合成することができる。合成方法の具体例を実施例の項で後述する。
ランタノイド系金属の具体例として、La、Pr、Nd、Gd、Sc、Y、Dy、Er、Yb、Sm、Eu、Tb、Ho、Tm、Luが挙げられ、さらに具体的には第二の実施形態に記載のものを用いることができる。
また、遷移金属の具体例として、Cu、Fe、Znが挙げられる。
このうち、製造工程における操作性を向上させる観点からは、反応溶媒をたとえば水とする。
また、たとえば水とアルコールの混合溶媒を用いることもでき、さらに具体的には水とメタノールの混合溶媒とすることもできる。
また、反応時間は、反応温度、撹拌効率等により設定することができるが、たとえば12~24時間程度とする。
具体的には、反応溶媒を水とし、反応温度を70℃以上、好ましくは75℃以上、また、100℃以下とすることにより、イソデスモシンまたはその誘導体を選択的に得ることができる。
また、反応溶媒を水とし、反応温度を0℃以上、好ましくは15℃以上、また、60℃以下、好ましくは40℃以下とすることにより、デスモシンまたはその誘導体と、イソデスモシンまたはその誘導体との両方を同一工程にて得ることができる。
また、反応時間は、反応温度、撹拌効率等により設定することができるが、たとえば12~24時間程度とする。
(工程22)一般式(XV)に示す化合物またはその塩を前記一般式(I)に示した化合物またはその塩に変換する工程。
工程22における脱保護方法については、第二の実施形態においてさらに具体的に説明する。
また、以下の実施形態においては、一般式(XIV)に示した金属のトリフルオロメタンスルホン酸塩として、ランタノイド塩を用いる場合を主に例に挙げて説明する。
本実施形態は、下記一般式(I)に示される製造方法に関する。本実施形態における製造方法は、以下の工程を含む。
(工程11)下記一般式(II)に示される化合物またはその塩と下記一般式(III)に示される化合物とを下記一般式(IV)に示されるランタノイド化合物の存在下に反応させて、下記一般式(V)に示される化合物またはその塩を形成する工程、および
(工程12)一般式(V)に示す化合物またはその塩を一般式(I)に示した化合物またはその塩に変換する工程。
(上記一般式(IV)中、LnはLa、Pr、Nd、Gd、Sc、Y、Dy、ErまたはYbであり、Tfはトリフルオロメチルスルホニル基である。)
一般式(I)において、R1が-CH2CH2CH2CH(NH2)COOH基であり、R2が水素原子である化合物が、式(1)に示したデスモシンである。また、R1が水素原子であり、R2が-CH2CH2CH2CH(NH2)COOH基である化合物が、式(2)に示したイソデスモシンである。
以下、工程11、工程12の順にさらに具体的に説明する。
上記原料のうち、アミノ基を有する化合物として一般式(II)に示した化合物またはその塩が用いられる。一般式(II)中、R3はBoc基またはCbz基であり、好ましくはBoc基である。また、R4はtBu基、Bn基、メチル基またはエチル基であり、好ましくはtBu基である。
一般式(II)に示した化合物の塩の具体例としては、一般式(II)における末端アミンの塩酸塩、トリフルオロメタンスルホン酸塩等が挙げられる。これらの塩を用いることにより、たとえば水溶性を高めることができる。
なお、一般式(III)に示した化合物は、公知の方法を用いて合成することができる。合成方法の具体例を実施例の項で後述する。
また、トリフルオロメタンスルホン酸塩として、一般式(IV)に示したLn塩にかえて、第一の実施形態に記載の他の金属塩を用いることもできる。
また、反応時間は、反応温度、撹拌効率等により設定することができるが、たとえば12~24時間程度とする。
たとえば、水とメタノールの混合溶媒を用いる場合、水に対するエタノールの割合を0体積倍より大きく10体積倍以下とし、一般式(III)に示した化合物を一般式(II)に示した化合物に対して1モル当量以上20モル当量以下使用することにより、R8が-CH2CH2CH2CH(N(R5)2)COOR6基でありR7が水素原子である化合物、つまりイソデスモシン誘導体をデスモシン誘導体に対して選択的に合成することができる。
また、工程11の溶媒を水とすることによって、デスモシン誘導体とイソデスモシン誘導体の両方を合成することができる。このとき、たとえば一般式(III)に示した化合物を一般式(II)に示した化合物に対して1モル当量以上10モル当量以下使用することにより、デスモシン誘導体とイソデスモシン誘導体の両方を合成することができる。
工程12においては、工程11で得られた一般式(V)の化合物中のアミノ基およびカルボキシル基を脱保護することにより、一般式(I)に示した化合物を得る。
たとえば、一般式(II)中のR3および一般式(III)中のR5がいずれもBoc基であり、一般式(II)中のR4がtBu基であり、一般式(III)中のR6がBn基である場合には、たとえば水素およびパラジウム炭素(Pd/C)を用いた接触還元によりBn基を除去する。接触還元の条件は、たとえばPd/C 500mol/%、室温(25℃、以下同じ。)、24時間とする。
次いで、たとえばトリフルオロ酢酸(TFA)水溶液等を用いた酸処理により、Boc基およびtBu基を除去することができる。酸処理の条件は、たとえばTFA/水=95/5、室温、2時間とする。
(工程10)一般式(VI)に示される化合物またはその塩を一般式(II)に示される化合物またはその塩に変換する工程。
(工程10-1)一般式(VI)に示した化合物を下記一般式(VII)に示す化合物に変換する工程、および
(工程10-2)一般式(VII)に示した化合物を一般式(II)に示した化合物またはその塩に変換する工程。
式(VI)に示した化合物として、市販のものを用いることができる。また、たとえばR4がtBu基の場合、実施例の項にて後述する方法のように、ウレア類を用いる反応によりtBu化することが好ましい。
たとえばR9がCbz基の場合、水素およびパラジウム炭素(Pd/C)を用いた接触還元によりCbz基を除去する。接触還元の条件は、たとえばPd/C 5mol/%、室温、2時間とする。
また、R9がBoc基の場合、TFAを用いた除去方法が好ましい。
工程10で得られた化合物は、工程11にて原料として用いることができる。
また、本実施形態によれば、原料として一般式(II)に示したアミノ酸誘導体および(III)に示したアミノ酸アルデヒドを用い、ランタノイド系化合物を触媒としたChichibabinピリジン合成を鍵反応とすることにより、デスモシン、イソデスモシンおよびこれらの誘導体を少ない工程数で収率良く得ることができる。また、ピリジン環を安定的に形成するとともに、ピリジン環の側鎖の位置を制御することも可能となる。
以上の実施形態において、一般式(I)に示した化合物またはその塩中、一または二以上の水素原子、一または二以上の炭素原子、あるいは一または二以上の窒素原子が、同位体で置換されていてもよい。たとえば、一または二以上の水素原子が重水素(D)で置換されていてもよい。また、一または二以上の炭素原子(12C)が13Cに置換されていてもよい。また、一または二以上の窒素原子(14N)が15Nに置換されていてもよい。一般式(I)に示した化合物を重水素等により同位体標識することにより、COPDバイオマーカーとして使用しうる化合物を安定的に得ることができる。
また、同位体標識する位置に特に制限はないが、側鎖の外れやすさの観点からは、ピリジン環の1位(N位)の側鎖を同位体標識するよりも、ピリジン環を構成する炭素原子に結合する側鎖を同位体標識することが好ましい。また、ピリジン環を構成する窒素または炭素原子を同位体置換してもよい。
同位体標識の方法に特に制限はないが、たとえば以下のスキーム1~3に示す方法が挙げられる。スキーム1~3中、黒丸(●)は13Cを示す。
一般式(III)に示した化合物の合成方法の具体例については、実施例の項で後述するが、一般式(III)に示した化合物の製造工程中、たとえばWittig反応の際に13Cを導入し、ヒドロホウ素化酸化でβ位にDを導入する。
そして、工程11において、一般式(III)に示した化合物として、上記同位体標識されたものを用いることにより、ピリジン環を構成する炭素原子を同位体置換するとともに、ピリジン環を構成する炭素原子に結合する側鎖中の水素原子を重水素化することができる。
この方法では、アリシン保護体にWittig反応において13Cを導入しておき、これと、市販の15Nの入ったリシン保護体とを用いて式(I)に示した化合物を合成する。Dを用いないため同位体率を低下させにくいという点で好ましい。
そして、工程11において、一般式(II)および一般式(III)に示した化合物として、それぞれ上記同位体標識されたものを用いることにより、ピリジン環を構成する炭素原子および窒素原子を同位体置換することができる。
そして、工程11において、一般式(III)に示した化合物として、上記重水素化したものを用いることにより、ピリジン環を構成する炭素原子に結合する側鎖中の水素原子を重水素化することができる。
[1]下記一般式(I)に示される化合物またはその塩の製造方法であって、
下記一般式(II)に示される化合物またはその塩と下記一般式(III)に示される化合物とを下記一般式(IV)に示されるランタノイド化合物の存在下に反応させて、下記一般式(V)またはその塩に示される化合物を形成する工程と、
前記一般式(V)に示す化合物またはその塩を前記一般式(I)に示した化合物またはその塩に変換する工程と、
を含む、製造方法。
Ln(OTf)3 (IV)
(上記一般式(IV)中、LnはLa、Pr、Nd、Gd、Sc、Y、Dy、ErまたはYbであり、Tfはトリフルオロメチルスルホニル基である。)
[2] [1]に記載の製造方法において、
下記一般式(VI)に示される化合物またはその塩を前記一般式(II)に示される化合物またはその塩に変換する工程をさらに含む、製造方法。
[3] [1]または[2]に記載の製造方法において、一般式(V)に示される化合物を形成する前記工程を、アルコールと水との混合溶媒中でおこなう、製造方法。
本例では、下記スキーム4に示す方法でアリシン保護体である化合物6を合成した。
市販のグルタミン酸保護体である化合物29(5.00g、1.0当量)のCH2Cl2(50mL)溶液にトリエチルアミン(Et3N)を1.5当量加え、混合物を0℃に冷却した。そして、N,N-ジメチル-4-アミノピリジン(DMAP、0.1当量)およびMeOCOCl(1.2当量)を順に添加した。得られた溶液を室温まで温め、0.5時間攪拌した。反応混合物をCH2Cl2で希釈し、1MのNaHCO3水溶液で洗浄した後、CH2Cl2で3回抽出した。得られた有機層をNa2SO4にて乾燥させた。シリカゲルカラムクロマトグラフィー(ヘキサン/EtOAc=2/1)により精製し、無色の油状物として化合物30を5.16g得た(収率99%)。
化合物30(0.50g、1.0当量)のMeCN(3.0mL)溶液に、DMAP(0.2当量)を加えた。得られた混合物に、(Boc)2O(4.0当量)のMeCN(2.0mL)溶液を加え、室温にて20時間攪拌した。シリカゲルカラムクロマトグラフィー(ヘキサン/EtOAc=3/1)より精製し、無色の油状物として化合物31を0.62g得た(収率97%)。
化合物31(2.00g、1.0当量)のEt2O(6.2mL)溶液を-78℃に冷却し、これに水素化ジイソブチルアルミニウム(DIBAL-H、ヘキサン中1M溶液、1.4当量)を3分間かけて滴下した。反応混合物を5分間攪拌した後、水(150μL)を加えて反応停止し、室温に戻した。得られた白色濃厚液をCelite(登録商標)粉末にて濾過し、Et2Oにて3回洗浄した。濾液を濃縮し、トルエンを用いた共沸により残留する微量の水を除去した。シリカゲルカラムクロマトグラフィー(ヘキサン/EtOAc=5/1)より精製し、無色の油状物として化合物32を1.66g得た(収率89%)。
本例では、化合物32をWittig反応により増炭し、化合物27を得た。
すなわち、メチルトリフェニルホスフィンブロミド(MePPh3Br、807mg、1.2当量)のTHF(20mL)懸濁液に、-78℃にてn-BuLi(ヘキサン中2.64M溶液、1.1当量)を滴下した。0℃に昇温し、得られた混合物を1.5時間攪拌した後、得られたイリド溶液に化合物32(0.793g、1.0当量)のTHF(10mL)溶液を添加した。0℃にて0.5時間攪拌した後、飽和NH4Cl水溶液にて反応を停止させた。EtOAcにて3回抽出した。有機層をあわせてNa2SO4により乾燥させた。シリカゲルカラムクロマトグラフィー(ヘキサン/EtOAc=19/1)より精製し、無色の油状物として化合物27を0.54g得た(収率68%)。
化合物27(0.455g、1.0当量)のTHF(3.0mL)溶液を0℃に冷却し、これにNaBH4(1.3当量)を添加した。10分間攪拌した後、この溶液にBF3・Et2O(1.3当量)を添加した。混合物を室温まで温め、26時間攪拌した。その後、溶液を0℃に冷却し、1M NaOH(1.5当量)を添加した後、30%H2O2(1.33mL)を添加し、3時間攪拌した。混合物を水で希釈し、EtOAcにて3回抽出した。有機層をあわせてNa2SO4により乾燥させた。シリカゲルカラムクロマトグラフィー(ヘキサン/EtOAc=1/1)より精製し、無色の油状物として化合物25を0.377g得た(収率80%)。
本例では、化合物25のDess-Martin酸化により、化合物6を得た。
すなわち、化合物25(100mg、0.229mmol)をジクロロメタン(2.86mL)に溶かし、0℃にした後、DMP(デス-マーチンペルヨージナン、145.4mg、0.343mmol)を加え1時間撹拌した。重曹/チオ硫酸ナトリウム=1/1の溶液を加え反応を停止し、酢酸エチルで抽出した。抽出した有機層を硫酸ナトリウムで乾燥、減圧下濃縮し、残渣をシリカゲルカラムクロマトグラフィー(ヘキサン/酢酸エチル=4/1)で単離精製を行い、化合物6を98%(97.6mg)で得た。
本例では、アリシン保護体である化合物54(2-(S)-Bis-tert-butoxycarbonylamino-6-oxo-hexanoic acid tert-butyl ester)を合成した。
以下の反応式により、化合物54を得た。
以下のスキーム5に示す手順により化合物53を合成し、得られた化合物53から化合物54を得た。
以下の式に示すように、化合物30を合成した。
以下の式に示すように、化合物11を合成した。
以下の式に示すように、化合物12を合成した。
以下の式に示すように、化合物13を合成した。
以下の式に示すように、化合物14を合成した。
以下の式に示すように、化合物15を合成した。
以下の式に示すように、化合物53を合成した。
以下の式に示すように、化合物54を合成した。
本例の方法により、ウレア系の化合物を用いずに式54の化合物を得ることができた。
本実施例においては、合成例1で得られた化合物6を用いて、イソデスモシンの全合成をおこなった。
実施例1において、化合物5および化合物6から化合物28を得る際の溶媒組成を変更し、実施例1に準じて合成反応をおこなった。
すなわち、反応溶媒について、実施例1では水/メタノールを2/1としたのに変えて、本例では水/メタノールを3/1とし、それ以外については実施例1に準じて化合物28を合成した。
その結果、本例においても化合物28を収率24%で得ることができた。
本例では、化合物5の塩酸塩5'(5-(S)-tert-Butoxycarbonyl-5-tert-butoxycarbonylamino-pentyl-ammonium chloride)を得た。
本例では、化合物4を原料として、化合物5の塩酸塩5'(5-(S)-tert-Butoxycarbonyl-5-tert-butoxycarbonylamino-pentyl-ammonium chloride)を得た。
本例では、以下のスキーム6に示す手順により、合成例2-2に記載の方法に準じて化合物12および18を合成し、さらに式5'の化合物を得た。
以下の式に示すように、化合物18を合成した。
以下の式に示すように、化合物16を合成した。
以下の式に示すように、化合物17を合成した。
以下の式に示すように、化合物5'を合成した。
本例の方法により、ウレア系の化合物を用いずに式5'の化合物を得ることができた。式12の化合物から式5'の化合物を得た際の総収率は26%となった。
本実施例は、デスモシン、イソデスモシンを一挙に合成できたChichibabinピリジン合成に関する。
具体的には、本実施例においては、合成例2で得られた化合物54および合成例3で得られた化合物5'を用いて、デスモシンおよびイソデスモシンの全合成をおこなった。
実施例3において、化合物5'および化合物54から化合物55、56を得る際の化合物5'および化合物54の仕込み組成比を変更し、それ以外については実施例3に準じて合成反応をおこなった。
また、化合物5'に変えて実施例1で使用した化合物5を用いるとともに、化合物5および化合物54の仕込み組成比を変更し、それ以外については実施例1に準じて合成反応をおこなった。
結果を表1に示す。表1より、原料の仕込み比および溶媒の組成比を調整することにより、デスモシンの合成中間体またはイソデスモシンの合成中間体の収率を調整することができる。
実施例3において、触媒として用いたLn(OTf)3の種類を変更し、それ以外については実施例1に準じて合成反応をおこなった。
結果を表2に示す。表2より、各種Ln(OTf)3を用いた場合にも、デスモシンの合成中間体およびイソデスモシンの合成中間体が得られた。
実施例3において、化合物5'および化合物54から化合物55、56を得る際の化合物5'および化合物54の仕込み組成比ならびに反応温度を変更し、それ以外については実施例1に準じて合成反応をおこなった。
結果を表3に示す。表3より、反応温度を80℃または100℃とすることにより、イソデスモシンの合成中間体を選択的に得ることができた。一方、室温または40℃においては、デスモシンの合成中間体およびイソデスモシンの合成中間体を得ることができた。
本例では、ピリジン環を構成する炭素原子および窒素原子が同位体標識されたデスモシン標識体およびイソデスモシン標識体の合成をおこなった。
[(6)-13C]-N,N-Bis[(1,1-dimethylethoxy)carbonyl]-6-oxo-1,1-dimethylethyl ester(化合物24)の合成手順をスキーム7に示す。
以下の式に示すように、化合物22を合成した。
以下の式に示すように、化合物23を合成した。
以下の式に示すように、化合物24を合成した。
以下の式に示すように、化合物41を合成した。
以下の式に示すように、化合物42を合成した。
2-{4'-(tert-butoxycarbonyl)-4'-(S)-[bis-(tert-butoxycarbonyl)-amino]-butyl}-3,5-bis-{3'-(tert-butoxycarbonyl)-3'-(S)-[bis-(tert-butoxycarbonyl)-amino]-propyl}-1-{5'-(tert-butoxcarbonyl)-5'-(S)-[bis-(tert-butoxycarbonyl)-amino]-pentyl}-pyridinium-13C (2), 13C (4), 13C (6), 15N (1)(化合物43)の合成
以下の式に示すように、化合物43を合成した。
以下の式に示すように、化合物44すなわちイソデスモシンの同位体標識体を得た。
Me:メチル
Et:エチル
Bu:ブチル
Ph:フェニル
Ac:アセチル
rt:室温
h:時間
d:日
Claims (5)
- 下記一般式(I)に示される化合物またはその塩の製造方法であって、
下記一般式(XII)に示される化合物またはその塩と下記一般式(XIII)に示される化合物とを下記一般式(XIV)に示される化合物の存在下に反応させて、下記一般式(XV)またはその塩に示される化合物を形成する工程を含む、製造方法。
M(OTf)3 (XIV)
(上記一般式(XIV)中、Mは3価の金属原子であり、Tfはトリフルオロメチルスルホニル基である。)
- 請求項1に記載の製造方法において、前記一般式(XII)におけるX1、Y1、前記一般式(XIII)におけるX2およびY2のうち、少なくとも1つが保護された基であり、
前記一般式(XV)に示す化合物またはその塩を前記一般式(I)に示した化合物またはその塩に変換する工程をさらに含む、製造方法。 - 請求項2に記載の製造方法において、
前記一般式(XII)に示した化合物またはその塩が、下記一般式(II)に示される化合物またはその塩であり、
前記一般式(XIII)に示した化合物が、下記一般式(III)に示される化合物である、製造方法。
- 請求項1乃至4いずれか一項に記載の製造方法において、一般式(XV)に示される化合物を形成する前記工程における反応溶媒を水とし、反応温度を70℃以上100℃以下とする、製造方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/765,068 US9556119B2 (en) | 2013-02-01 | 2014-01-24 | Process for preparing desmosine, isodesmosine, and derivatives thereof |
JP2014559652A JP6233934B2 (ja) | 2013-02-01 | 2014-01-24 | デスモシン、イソデスモシン、およびその誘導体の製造方法 |
EP14746701.3A EP2952504B1 (en) | 2013-02-01 | 2014-01-24 | Method for producing desmosine, isodesmosine and derivatives thereof |
CN201480007160.7A CN104981456B (zh) | 2013-02-01 | 2014-01-24 | 锁链素、异锁链素以及它们的衍生物的制造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013-018473 | 2013-02-01 | ||
JP2013018473 | 2013-02-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014119479A1 true WO2014119479A1 (ja) | 2014-08-07 |
Family
ID=51262193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/051482 WO2014119479A1 (ja) | 2013-02-01 | 2014-01-24 | デスモシン、イソデスモシン、およびその誘導体の製造方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9556119B2 (ja) |
EP (1) | EP2952504B1 (ja) |
JP (1) | JP6233934B2 (ja) |
CN (1) | CN104981456B (ja) |
WO (1) | WO2014119479A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019108304A (ja) * | 2017-12-19 | 2019-07-04 | 学校法人上智学院 | デスモシンおよびイソデスモシンの製造方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4723012A (en) * | 1985-03-25 | 1988-02-02 | Japan Tobacco Inc. | Desmosine derivatives having a disulfide bond and preparation of artificial antigen using the same |
IL114314A (en) * | 1994-06-24 | 2000-12-06 | Reilly Ind Inc | Amination of pyridine bases |
WO2006046626A1 (ja) * | 2004-10-29 | 2006-05-04 | Kyushu Institute Of Technology | 水溶性エラスチンとその製造方法及びそれを含む食品と医薬 |
-
2014
- 2014-01-24 EP EP14746701.3A patent/EP2952504B1/en active Active
- 2014-01-24 CN CN201480007160.7A patent/CN104981456B/zh active Active
- 2014-01-24 JP JP2014559652A patent/JP6233934B2/ja active Active
- 2014-01-24 US US14/765,068 patent/US9556119B2/en active Active
- 2014-01-24 WO PCT/JP2014/051482 patent/WO2014119479A1/ja active Application Filing
Non-Patent Citations (9)
Title |
---|
AKAGAWA,M. ET AL.: "Mechanism of formation of elastin crosslinks", CONNECTIVE TISSUE RESEARCH, vol. 41, no. 2, 2000, pages 131 - 141, XP008180233 * |
DAVIS,N.R. ET AL.: "On the mechanism of formation of desmosine and isodesmosine cross-links of elastin", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 92, no. 12, 1 June 1970 (1970-06-01), pages 3778 - 3782, XP055272390, DOI: 10.1021/JA00715A040 * |
HIROTO YANUMA: "Total synthesis of the COPD biomarker desmosine via Sonogashira and Negishi cross-coupling reactions", TETRAHEDRON LETT., vol. 53, 2012, pages 5920 - 5923 |
LI-BING YU: "Lanthanide-Promoted Reactions of Aldehydes and Amine Hydrochlorides in Aqueous Solution. Synthesis of 2,3-Dihydropyridinium and Pyridinium Derivatives", J. ORG. CHEM., vol. 62, 1997, pages 208 - 211 |
NAKANISHI,T. ET AL.: "Formation of phosphatidyl 1-(2-hydroxyethyl)-2,3,5-trialkyl pyridinium on heating phosphatidyl ethanolamine with n-alkanal", AGRICULTURAL AND BIOLOGICAL CHEMISTRY, vol. 38, no. 6, 1 June 1974 (1974-06-01), pages 1141 - 1147, XP055272397, DOI: 10.1080/00021369.1974.10861304 * |
TOYONOBU USUKI: "Total synthesis of COPD biomarker desmosine that crosslinks elastin", CHEM. COMMUN., vol. 48, 2012, pages 3233 - 3235 |
YOHEI KOSEKI: "Efficient synthesis of benzyl 2-(S) -[(tert-butoxycarbonyl)amino] -?-iodoalkanoates", TETRAHEDRON: ASYMMETRY, vol. 22, 2011, pages 580 - 586 |
YOHEI KOSEKI: "Efficient synthesis of benzyl 2-(S) -[(tert-butoxycarbonyl)amino] -co-iodoalkanoates", TETRAHEDRON: ASYMMETRY, vol. 22, 2011, pages 580 - 586 |
YU ,L. ET AL.: "Lanthanide-Promoted Reactions of Aldehydes and Amine Hydrochlorides in Aqueous Solution. Synthesis of 2,3-Dihydropyridinium and Pyridinium Derivatives", JOURNAL OF ORGANIC CHEMISTRY, vol. 62, no. 1, 1 January 1997 (1997-01-01), pages 208 - 211, XP055272393 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019108304A (ja) * | 2017-12-19 | 2019-07-04 | 学校法人上智学院 | デスモシンおよびイソデスモシンの製造方法 |
JP7020669B2 (ja) | 2017-12-19 | 2022-02-16 | 学校法人上智学院 | デスモシンおよびイソデスモシンの製造方法 |
Also Published As
Publication number | Publication date |
---|---|
US9556119B2 (en) | 2017-01-31 |
CN104981456B (zh) | 2017-12-19 |
JPWO2014119479A1 (ja) | 2017-01-26 |
EP2952504A4 (en) | 2016-07-06 |
JP6233934B2 (ja) | 2017-11-22 |
CN104981456A (zh) | 2015-10-14 |
EP2952504B1 (en) | 2017-10-11 |
US20150376127A1 (en) | 2015-12-31 |
EP2952504A1 (en) | 2015-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2341044B1 (en) | Cycloalkylamine derivative | |
KR20220149558A (ko) | Gpr40 작용제 | |
KR102629923B1 (ko) | 피롤리딘 화합물 | |
JP6233934B2 (ja) | デスモシン、イソデスモシン、およびその誘導体の製造方法 | |
CN111471003B (zh) | 一种立他司特中间体的制备方法 | |
US7803960B2 (en) | Phenyloxyaniline derivatives | |
Shing et al. | An alternative synthesis of 1, 1′-Bis-valienamine from d-glucose | |
JP7020669B2 (ja) | デスモシンおよびイソデスモシンの製造方法 | |
JP2010508334A (ja) | アミノベンゾシクロヘプテン誘導体、その調製方法及び治療におけるその使用 | |
US6252082B1 (en) | Pyridone derivatives, their preparation and their use as synthesis intermediates | |
JP5204438B2 (ja) | 含フッ素アミン化合物の製造方法 | |
CN111499660A (zh) | 一种手性磺酰胺脯氨酸类双官能催化剂及其制备方法和应用 | |
JP7020679B2 (ja) | 同位体標識化合物の製造方法 | |
JP2009057359A (ja) | アミンボランを用いる含フッ素アミン化合物の製造方法 | |
US10280143B1 (en) | Process for preparing deuterated desmosine and derivatives thereof | |
JP5279449B2 (ja) | 5−{4−[2−(5−エチル−2−ピリジル)エトキシ]ベンジル}−2,4−チアゾリジンジオン塩酸塩の製造方法 | |
CN117865880A (zh) | 一种kx2-361-d4苯磺酸盐的合成工艺 | |
US20040054185A1 (en) | Process for preparing amine-substituted benzofurans | |
JP3272170B2 (ja) | ピリジン誘導体の製造法 | |
JP5854213B2 (ja) | 光学活性アミン化合物の製造方法 | |
CN111377867A (zh) | 一种合成2-(1-烷基-1h-吡唑-4-基)吗啉的中间体及其制备方法和应用 | |
JP2019023167A (ja) | 1,3−ピレンジカルボアルデヒドを製造するための方法とその合成中間体 | |
JPH0160469B2 (ja) | ||
KR19990085359A (ko) | 파라 및(또는) 메타-치환된 시아노페닐알라닌 유도체의 제조방법 | |
JP2011020944A (ja) | ポジトロン放出源化合物の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14746701 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014559652 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14765068 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2014746701 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014746701 Country of ref document: EP |